{"nctId":"NCT03692312","briefTitle":"Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy","startDateStruct":{"date":"2021-03-03","type":"ACTUAL"},"conditions":["Congenital Myotonic Dystrophy"],"count":56,"armGroups":[{"label":"Tideglusib","type":"EXPERIMENTAL","interventionNames":["Drug: Tideglusib","Drug: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tideglusib","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female children and adolescents aged ≥6 years and ≤16 years\n2. Diagnosis of Congenital DM1 (also known as Steinert's disease)\n\n   * Diagnosis must be genetically confirmed\n   * One or more of the following clinically relevant (e.g. requiring medical intervention) signs or symptoms was evident within the first month after birth:\n\n     * Hypotonia\n     * Generalized weakness\n     * Respiratory insufficiency\n     * Feeding difficulties\n     * Clubfoot or another musculoskeletal deformity\n3. Subject must be able to walk and complete the 10-meter walk-run test (orthotics/splints allowed, forearm crutches are not allowed)\n4. Written, voluntary informed consent must be obtained before any study related procedures are conducted.\n\n   * Where a parent or LAR provides consent, there must also be assent from the subject\n5. Subject's caregiver must be willing and able to support participation for duration of study\n6. Subject must be willing and able to comply with the required food intake restrictions as outlined per protocol\n\nExclusion Criteria:\n\n1. Not able to walk; (full time wheel chair use)\n2. Body mass index (BMI) less than 13.5 kg/m² or greater than 40 kg/m²\n3. New or change in medications/therapies within 4 weeks prior to Screening\n4. Use of strong CYP3A4 inhibitors (e.g clarithromycin, telithromycin, ketoconazole, itraconazole, posaconazole, nefazodone, idinavir and ritonavir) within 4 weeks prior to Baseline\n5. Concurrent use of drugs metabolized by CYP3A4 with a narrow therapeutic window (e.g. warfarin and digitoxin)\n6. Current enrollment in a clinical trial of an investigational drug or enrollment in a clinical trial of an investigational drug in the last 6 months\n7. Existing or historical medical conditions or complications (e.g. neurological, cardiovascular, renal, hepatic, endocrine, gastrointestinal or respiratory disease) which would cause the investigator to conclude that the subject will not be able to perform the study procedures or assessments or would confound interpretation of data obtained during assessment\n8. Hypersensitivity to tideglusib and its excipients including allergy to strawberry","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS)","description":"The Clinician-Completed Congenital DM1 Scale is an 11-item rating scale completed by the clinician that scores the symptom severity of domains that are clinically relevant in Congenital DM1.\n\nThe severity of the clinician's concern in each domain is scored by using a 5-point Likert Scale. Scores range from 0 = Not present to 4 = Very severe.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.65","spread":"0.620"},{"groupId":"OG001","value":"-3.40","spread":"0.618"}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Global Impression- Improvement Scale (CGI-I) Scores","description":"The clinician administered CGI-I rates how much the subject's illness has improved or worsened relative to a baseline state.\n\nA 7-point Likert type scale is used with ratings of 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.11","spread":"0.190"},{"groupId":"OG001","value":"2.77","spread":"0.189"}]}]}]},{"type":"SECONDARY","title":"Change in Top 3 Caregiver Concerns Visual Analogue Scale (VAS) Score","description":"The Top 3 concerns VAS allows caregivers to identify their main three causes of concern, related to the subject's myotonic dystrophy, rather than these being pre-specified within a scale and then rating how these concerns have changed at specific time-points during the study. Caregivers were asked to rate three causes for concern by drawing a vertical mark on a 10 cm long VAS with anchors of \"not at all severe\" at the left end (0 cm) and \"very severe\" at the right end (10 cm). A score for each concern was to be determined by measuring the number of centimeters on the 10 cm VAS line from the anchor point on the left side of the line. A total VAS score for each subject was calculated as the sum of the scores for the 3 concerns (minimum = 0 cm, maximum = 30 cm). A higher score represents a worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.74","spread":"0.780"},{"groupId":"OG001","value":"-6.47","spread":"0.780"}]}]}]},{"type":"SECONDARY","title":"Caregiver Completed Congenital DM1 Rating Scale (CC-CDM1-RS)","description":"The Caregiver-Completed Congenital DM1 Scale is a caregiver assessment of the subject on symptoms that may occur in individuals with CDM1. There are a total of 11 clinically relevant symptoms that the caregiver is asked to rate the severity of.\n\nThe symptoms are rated on a score from 0 to 4 based on overall severity where 0 = symptom not present or is no longer present during the relevant time frame, and 4 = very severe, symptom causes pronounced and consistent impairment and is highly disruptive with regard to daily life. A total CC-CDM1-RS score for each subject was calculated as the sum of the scores where 0 = min and 44 = max. A higher score represents a worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.770"},{"groupId":"OG001","value":"-3.36","spread":"0.782"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression - Severity Scale (CGI-S)","description":"The Clinical Global Impression - Severity Scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the subject's illness at the time of assessment, relative to the clinician's past experience with subjects who have the same diagnosis.\n\nSubjects are assessed on severity of illness at the time of rating 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.076"},{"groupId":"OG001","value":"-0.12","spread":"0.076"}]}]}]},{"type":"SECONDARY","title":"10-meter Walk-run Test","description":"The 10-meter walk/run test is a performance measure used to assess walking speed in seconds over a short distance. It can be used as an assessment of functional mobility.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"0.393"},{"groupId":"OG001","value":"-0.19","spread":"0.391"}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events (AEs), Including Serious Adverse Events (SAEs), Between Screening to End of Study.","description":"Adverse events may be volunteered spontaneously by the subject, or discovered as a result of general, non-leading questioning by physician.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Abnormal Findings in Objective Assessments (e.g. Laboratory Values, ECGs, Vital Signs and Bone Mineral Density) Between Screening and End of Study.","description":"Abnormal laboratory findings (e.g. hematology, liver function, biochemistry, urinalysis) or other abnormal assessments (e.g. ECGs, vital signs) that are judged by the Investigator as clinically significant will be recorded as AEs or SAEs if they meet the definition of an AE. The Investigator will exercise his or her medical and scientific judgment in deciding whether an abnormal laboratory finding or other abnormal assessment is clinically significant.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"CDM1-RS Independent Central Rater Score (CDM1-RS)","description":"Change from baseline to end of treatment in the independent central rater CDM1-RS total score. CDM1 Rating Scale is an 11-item rating scale completed by the clinician to score the symptom severity that are clinically relevant in CDM1.\n\nThe severity of the clinician's concern in each domain is scored by using a 5-point Likert Scale. Scores range from 0 = Not present to 4 = Very severe.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.26","spread":"0.533"},{"groupId":"OG001","value":"-2.55","spread":"0.547"}]}]}]},{"type":"SECONDARY","title":"CGI-I Independent Central Rater Score (CGI-I)","description":"The CGI-I requires the clinician to rate how much the subject's illness has changed (improved, worsened or stayed the same) relative to a baseline state on a seven point scale.\n\nA 7-point Likert type scale is used with ratings of 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.74","spread":"0.227"},{"groupId":"OG001","value":"2.65","spread":"0.234"}]}]}]},{"type":"SECONDARY","title":"Independent Rater Clinical Global Impression - Severity Scale (CGI-S)","description":"CGI-S is a 7-point Likert type scale. An independent central rater rated the CGI-S scales for both the in-clinic and telehealth interviews.\n\nSubjects are assessed on severity of illness at the time of rating 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"0.080"},{"groupId":"OG001","value":"-0.21","spread":"0.093"}]}]}]},{"type":"POST_HOC","title":"MDRI Analysis","description":"A multi-domain responder index (MDRI) analysis was performed by combining 5 endpoints to objectively assess movement, muscle integrity and strength, cognitive skills and adaptive behavior. For each of the 5 endpoints, subjects were scored +1 point if their change exceeded or was equal to the threshold in a beneficial direction, -1 point if their change exceeded or was equal to the threshold in a detrimental direction and 0 points otherwise. The sum of these 5 scores were added together to provide an MDRI score between -5 and 5, where a higher score indicates greater overall improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.31"},{"groupId":"OG001","value":"-0.1","spread":"0.25"}]}]}]},{"type":"POST_HOC","title":"Creatine Phosphokinase","description":"Analysis of Ratio to Baseline in Creatine Phosphokinase","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":null},{"groupId":"OG001","value":"1.05","spread":null}]}]}]},{"type":"POST_HOC","title":"Mean Group Difference in 10 Meter Walk/ Run","description":"Post-hoc analyses comparing the mean clinical responses of subjects with tideglusib exposures above the 50th percentile (who achieved the desired target exposure) with those subjects who showed lower exposure levels, and with the placebo group.\n\nThe 10-meter walk/run test is a performance measure used to assess walking speed in seconds over a short distance. It can be used as an assessment of functional mobility.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"8.7","spread":null},{"groupId":"OG002","value":"8.5","spread":null}]}]}]},{"type":"POST_HOC","title":"Mean Change From Baseline Group Difference in 10 Meter Walk/ Run","description":"Post-hoc analyses comparing the mean change from baseline from clinical responses of subjects with tideglusib exposures above the 50th percentile (who achieved the desired target exposure) with those subjects who showed lower exposure levels, and with the placebo group.\n\nThe 10-meter walk/run test is a performance measure used to assess walking speed in seconds over a short distance. It can be used as an assessment of functional mobility.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.7"},{"groupId":"OG001","value":"-1.5","spread":"2.2"},{"groupId":"OG002","value":"-0.1","spread":"1.8"}]}]}]},{"type":"POST_HOC","title":"Mean Group Difference in Peabody Picture Vocabulary Test (PPVT)","description":"Post-hoc analyses comparing the mean clinical responses of subjects with tideglusib exposures above the 50th percentile (who achieved the desired target exposure) with those subjects who showed lower exposure levels, and with the placebo group. The PPVT-4 scale is a norm-referenced instrument for measuring the receptive (hearing) vocabulary. It contains training items and 228 test items, each consisting of four full-color pictures as response options on a page. For each item, the examiner says a word and the examinee responds by selecting the picture that best illustrates that word's meaning. Each test produces a raw score (number of test items answered correctly) and a standard score (using age-based norms to convert raw score into a score with a mean of 100 and a standard deviation of 15). Raw scores are reported here as standardized scores are considered less appropriate for a pediatric population with cognitive deficits. Higher scores mean a better performance/receptive vocabulary","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"134","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]}]},{"type":"POST_HOC","title":"Mean Change From Baseline Group Difference in Peabody Picture Vocabulary Test (PPVT)","description":"Post-hoc analyses comparing the mean change from baseline clinical responses of subjects with tideglusib exposures above the 50th percentile (who achieved the desired target exposure) with those subjects who showed lower exposure levels, and with the placebo group. The PPVT-4 scale is a norm-referenced instrument for measuring the receptive (hearing) vocabulary. It contains training items and 228 test items, each consisting of four full-color pictures as response options on a page. Each test produces a raw score and a standard score. The raw score counts the number of correct responses. Raw scores are reported here as standardized scores are considered less appropriate for a pediatric population with cognitive deficits. Higher scores mean a better performance/receptive vocabulary. The lowest possible raw score is 0, the maximum raw score depends on the number of items administered so theoretically, the highest score possible on this test would be 228.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"14"},{"groupId":"OG001","value":"6","spread":"17"},{"groupId":"OG002","value":"-2","spread":"10"}]}]}]},{"type":"POST_HOC","title":"Mean Group Difference in Creatine Phosphokinase","description":"Post-hoc analyses comparing the mean clinical responses of subjects with tideglusib exposures above the 50th percentile (who achieved the desired target exposure) with those subjects who showed lower exposure levels, and with the placebo group.\n\nConcentration of Creatine Phosphokinase (UI/L).","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"195","spread":null},{"groupId":"OG002","value":"299","spread":null}]}]}]},{"type":"POST_HOC","title":"Mean Change From Baseline Group Difference in Creatine Phosphokinase","description":"Post-hoc analyses comparing the mean change from baseline in clinical responses of subjects with tideglusib exposures above the 50th percentile (who achieved the desired target exposure) with those subjects who showed lower exposure levels, and with the placebo group.\n\nConcentration of Creatine Phosphokinase (UI/L).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17","spread":"27"},{"groupId":"OG001","value":"-65","spread":"147"},{"groupId":"OG002","value":"30","spread":"138"}]}]}]},{"type":"POST_HOC","title":"Mean Group Difference in MDRI","description":"Post-hoc analyses comparing the mean clinical responses of subjects above and below the 50th percentile of tideglusib exposure levels with the placebo group. A multi-domain responder index (MDRI) analysis was performed by combining 5 objective endpoints. For each of the 5 endpoints, subjects were scored +1 point if their change exceeded or was equal to the threshold in a beneficial direction, -1 point if their change exceeded or was equal to the threshold in a detrimental direction and 0 points otherwise. The sum of these 5 scores were added together to provide an MDRI score between -5 and 5, where a higher score indicates greater overall improvement.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"-0.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":28},"commonTop":["Diarrhea","Nasopharyngytitis","Upper respiratory tract infection","Vomiting","Cough"]}}}